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Abstract: 
 
Birth weight variation is influenced by fetal and maternal genetic and non-genetic factors, 
and has been reproducibly associated with future cardio-metabolic health outcomes. In 
expanded genome-wide association analyses of own birth weight (n=321,223) and offspring 
birth weight (n=230,069 mothers), we identified 190 independent association signals (129 
novel). We used structural equation modelling to decompose the contributions of direct 
fetal and indirect maternal genetic effects, and then applied Mendelian randomization to 
illuminate causal pathways. For example, both indirect maternal and direct fetal genetic 
effects drive the observational relationship between lower birth weight and higher later 
blood pressure: maternal blood pressure-raising alleles reduce offspring birth weight, but 
only direct fetal effects of those alleles, once inherited, increase later offspring blood 
pressure. Using maternal birth weight-lowering genotypes to proxy for an adverse 
intrauterine environment provided no evidence that it causally raises offspring blood 
pressure, indicating that the inverse birth weight-blood pressure association is attributable 
to genetic effects, and not to intrauterine programming.
 10 
Birth weight is an important predictor of newborn and infant survival, a key indicator of 
pregnancy outcomes, and is observationally associated with future risk of adult cardio-
metabolic diseases in the offspring. These observational associations are often assumed to 
reflect adaptations made by a developing fetus in response to an adverse intrauterine 
environment, a concept termed the Developmental Origins of Health and Disease (DOHaD)1. 
Support for DOHaD is primarily from animal models (reviewed in 2). Observational studies of 
famine-exposed populations support prenatal programming in relation to type 2 diabetes 
(T2D), but not other cardio-metabolic health measures (reviewed in 3). However, DOHaD 
cannot provide a complete explanation for the relationship between lower birth weight and 
increased risk of cardio-metabolic disease. Other likely contributing factors are (i) 
environmental confounding, leading to phenotypic associations across the life-course4, and 
(ii) shared genetic effects operating at the population level5. Genetic associations between 
birth weight and later cardio-metabolic diseases may arise from the direct effects of the 
same inherited genetic variants at different stages of the life-course6. However, 
consideration of an individual’s own genotype in isolation cannot exclude potential 
confounding by any indirect effects of the correlated maternal genotype (r≈0.5) on the 
intrauterine, and possibly postnatal, environment. Evidence for maternal indirect effects on 
birth weight and later offspring disease risk could implicate the intrauterine environment in 
later-life disease etiology. 
 
To date, 65 genetic loci have been associated with birth weight in genome-wide association 
studies (GWAS), implicating biological pathways that may underlie observational 
associations with adult disease5,7-9. However, most of those studies did not distinguish 
between maternal and fetal genetic influences. Evidence from monogenic human models10 
and variance components analyses11 demonstrate that birth weight is influenced both by 
genotypes inherited by the fetus and by maternal genotypes that influence the intrauterine 
environment. To date, GWAS of own birth weight5, and maternal GWAS of offspring birth 
weight7, have produced overlapping signals due to the correlation between maternal and 
fetal genotypes. Identified birth weight variants might have (i) a direct fetal effect only, (ii) 
an indirect maternal effect only, or (iii) some combination of the two. Performing separate 
GWAS analyses of own or offspring birth weight precludes full resolution of the origin of the 
identified genetic effects.  
 
To address these issues, we performed greatly-expanded GWAS of own (n=321,223) and 
offspring birth weight (n=230,069 mothers) using data from the EGG Consortium and the UK 
Biobank (2017 release). We applied a structural equation model that we recently developed 
to partition genetic effects on birth weight into maternal and fetal components at genome-
wide significant loci7,12. We then extended the method to estimate maternal- and fetal-
specific genetic effects across the genome in a computationally efficient manner, and used 
the results for downstream analyses. Our ability to resolve maternal and fetal genetic 
contributions provides substantial insights into the underlying biological regulation of birth 
weight and into the origins of observational relationships with T2D and blood pressure.
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RESULTS 
 
Meta-analyses of fetal and maternal GWAS  
We conducted GWAS meta-analyses of own (fetal) genetic variants on own birth weight 
(Supplementary Figure 1, Supplementary Tables 1, 2) and maternal genetic variants on 
offspring birth weight (Supplementary Figure 2, Supplementary Tables 3, 4) in individuals 
of European ancestry. We then performed approximate conditional and joint multiple-SNP 
analysis (COJO13) and a trans-ethnic meta-analysis to identify further independent SNPs 
(Methods). The GWAS meta-analysis of own birth weight (N=321,223) identified 146 
independent single nucleotide polymorphisms (SNPs) at genome-wide significance 
(P<6.6x10-9; Supplementary Figures 3, 4, 5a, Supplementary Table 5a, Methods). The 
GWAS meta-analysis of offspring birth weight (N=230,069 mothers) identified 72 
independent SNPs (P<6.6x10-9; Supplementary Figures 3, 4, 5b, Supplementary Table 5a, 
Methods). Applying the more lenient significance threshold used previously (P<5x10-8)5,7, 
211 SNPs and 105 SNPs reached significance for own and offspring birth weight, respectively 
(Supplementary Table 5b). 
 
SNPs at 30 genome-wide significant loci (within 500Kb and r2 ≥ 0.1) were identified in the 
GWAS of both own and offspring birth weight. Of these, 9 loci had the same lead SNP and 
21 loci had fetal and maternal lead SNPs correlated with r2 ≥ 0.1. Colocalization analysis 
indicated 19/21 of these correlated lead SNP pairs were likely tagging the same birth weight 
signal (posterior probability > 0.5). Therefore, we identified a total of 190 independent 
association signals, represented by 209 lead SNPs (Supplementary Figure 4, Supplementary 
Table 5a). Of the 209 lead SNPs, 146 were novel representing 129 independent association 
signals, three are rare (minor allele frequency (MAF)<1%) and 13 are low-frequency 
(1%≤MAF<5%). The three rare variants (at the YKT6/GCK, ACVR1C and MIR146B loci) alter 
birth weight by more than double the effect (>100g per allele) of the first common variants 
identified9. In the independent Norwegian MoBa-HARVEST study (N=13,934 mother-
offspring duos), the lead SNPs explained 7% of the variance in birth weight, calculated as the 
sum of variances explained by the fetal genotype (6%), maternal genotype (2%), plus twice 
the covariance (-0.5%). Maternal genome-wide complex trait analysis (M-GCTA11), which 
estimates SNP-heritability and partitions this quantity into maternal and fetal components, 
estimated that 39.8% of the variance in birth weight could be explained by tagged fetal 
genetic variation (28.5%), tagged maternal genetic variation (7.6%) and twice the covariance 
(3.7%). 
 
We integrated data from several sources to highlight possible causal genes underlying the 
identified associations, including gene-level expression data across 43 tissues (from GTEx 
v6p14), placental expression quantitative trait loci (eQTL)15, topologically associating 
domains (TADs) identified in human embryonic stem cells16,17 and non-synonymous SNPs 
(see Supplementary Tables 5a, 5b; Methods). Several genes were highlighted by multiple 
approaches; however, further functional studies are required to confirm causality.  
 
Structural equation model to estimate maternal and fetal effects  
We next partitioned the 209 lead SNPs into five categories based on their maternal and/or 
fetal genetic contributions to birth weight. To achieve this, we used structural equation 
modelling (SEM) that accounts for the correlation between fetal and maternal genotypes 
 12 
and thereby provides unbiased estimates of the maternal and fetal genetic effects on birth 
weight12 (see Methods and Supplementary Figure 6a for details). The results are presented 
in Figure 1, Supplementary Figures 4, 7 and Supplementary Table 5. Using the confidence 
intervals around the SEM-adjusted maternal and fetal effect estimates, we identified 64 
SNPs with fetal-only effects, 32 SNPs with maternal-only effects, 27 SNPs with directionally-
concordant fetal and maternal effects, and 15 SNPs with directionally-opposing fetal and 
maternal effects (Supplementary Figure 8). For example, rs10830963 at MTNR1B was 
identified in both the own birth weight (P=2.8x10-11) and offspring birth weight (P=9.1x10-39) 
GWAS, but the SEM analysis revealed that its effect was exclusively maternal (PSEMfetal=0.7, 
PSEMmaternal=4.6x10-19). In contrast, rs560887 at G6PC2 was identified only in the GWAS of 
offspring birth weight (P=1.2x10-14), but was found to have directionally-opposing maternal 
and fetal effects (βSEMfetal=-0.03, PSEMfetal=2.8x10-8; βSEMfetal=0.04, PSEMmaternal=5.4x10-14). At 
present, these categories are suggestive as the current sample size has insufficient statistical 
power to detect small genetic effects, particularly maternal effects. There were 71 
unclassified SNPs, and some that were classified as fetal only, for example, may have had a 
small, undetected maternal effect. Asymptotic power calculations showed we had 80% 
power to detect fetal (maternal) effects that explained 0.006% (0.008%) of the variance in 
birth weight (α=0.05). However, there was strong consistency with traditional conditional 
linear regression modelling in N=18,873 mother-offspring pairs (Supplementary Table 6, 
Methods), and overall, the method gave a clear indication as to which genetic associations 
are driven by the maternal or fetal genomes. 
 
To extend the estimates of adjusted maternal and fetal effects genome-wide, we developed 
a weighted linear model (WLM) (see Methods), which yields a good approximation to the 
SEM with equivalent estimates for the 209 lead SNPs (Supplementary Figure 9). This was 
necessary because the SEM is too computationally intensive to fit across the genome. The 
adjusted fetal and maternal genotype effect estimates on birth weight from the WLM are 
hereafter referred to as WLM-adjusted estimates. Using linkage disequilibrium (LD) score 
regression18, we observed that the genetic correlation between the WLM-adjusted maternal 
and fetal effects (rg=0.10, P=0.12) was substantially lower than that between the unadjusted 
effects from the original GWAS (rg=0.82, P<0.01), indicating that the WLM largely accounts 
for the underlying correlation between fetal and maternal genotypes. No additional novel 
loci were identified, but we used the WLM-adjusted estimates in downstream analyses to 
identify fetal- and maternal-specific mechanisms that regulate birth weight and to 
investigate the genetic links between birth weight and adult traits. 
 
Maternal- and fetal-specific tissues and mechanisms underlying birth weight regulation 
Tests of global enrichment of birth weight SNP associations across tissues sampled from the 
GTEx project14 using LD-SEG19 are presented in Supplementary Figure 10. Only enrichment 
for maternal-specific SNP associations for genes expressed in connective/bone tissues was 
detected after Bonferroni correction. Integration of epigenetic signatures defined by the 
Roadmap Epigenomics project highlighted a significant enrichment of maternal-specific 
effects in the ovary for histone modification marks (H3K4me1) and regions of open 
chromatin (Supplementary Table 7); no significant enrichment was detected for other 
signatures. Gene-set enrichment analysis implicated different fetal-specific (Supplementary 
Table 8) and maternal-specific (Supplementary Table 9) gene sets.  
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A major determinant of birth weight is the duration of gestation. Using LD score 
regression18, we found a substantial genetic correlation between published maternal 
genetic effects on gestational duration20 and the WLM-adjusted maternal effects on 
offspring birth weight (rg=0.63; P=2.1x10-5; Supplementary Table 10; Methods), but not 
with the WLM-adjusted fetal effects on own birth weight (rg=-0.10, P=0.34). Gestational 
duration was unavailable for >85% of individuals in the birth weight GWAS analyses, so it is 
possible that some identified association signals influence birth weight primarily by altering 
gestational duration. We looked up the 209 lead birth weight-associated SNPs in the 
published maternal GWAS of gestational duration20 (Supplementary Table 11) and followed 
up 7 associated SNPs (P<2.4x10-4, corrected for 209 tests, Methods) in 13,206 mother-child 
pairs. Meta-analysis with summary data from 23andMe20 strengthened associations with 
gestational duration at 5/7 loci (EBF1, AGTR2, ZBTB38, KCNAB1 and KLHL25/AKAP13; 
Supplementary Table 12). The precise causal relationship between fetal growth and 
gestational duration at these loci requires further investigation, however, the majority of 
associations with birth weight do not appear to be driven by associations with gestational 
duration. 
 
Maternal- and fetal-specific genetic correlations between birth weight and adult traits 
The 209 lead birth weight-associated SNPs were associated with other phenotypes in 
previously-published GWAS and the UK Biobank (Supplementary Table 13, Methods). At 
the genome-wide level, we previously reported genetic correlations between own birth 
weight and several adult cardio-metabolic traits5 but were unable to distinguish the direct 
fetal genotype contribution from the indirect contribution of maternal genotype. To 
understand these distinct contributions, we calculated genetic correlations using LD score 
regression18 between WLM-adjusted fetal and maternal SNP effect estimates and GWAS 
estimates for a range of traits (Figure 2, Supplementary Table 10, Methods). For many 
traits (e.g. adult height), the fetal-specific genetic correlation was similar to the maternal-
specific genetic correlation, but for some traits, the fetal-specific and maternal-specific 
genetic correlations were different in magnitude (e.g. SBP) or even in direction (e.g. T2D). 
For several glycemic traits, (e.g. fasting glucose) the genetic correlations estimated using the 
WLM-adjusted effects were substantially different from those estimated using the 
unadjusted effects, demonstrating the importance of accounting for the maternal-fetal 
genotype correlation.  
 
Using genetics to estimate causal effects of intrauterine exposures on birth weight 
The separation of direct fetal genotype effects from indirect maternal genotype effects on 
birth weight offers the novel opportunity to estimate unconfounded causal influences of 
intrauterine exposures using Mendelian randomization (MR) analyses. The principle of MR is 
similar to that of a randomized controlled trial: parental alleles are randomly transmitted to 
offspring and are therefore generally free from confounding21,22. Consequently, an 
association between a maternal genetic variant for an exposure of interest, and offspring 
birth weight, after accounting for fetal genotype, provides evidence that the maternal 
exposure is causally related to offspring birth weight (Figure 3a). Previous attempts to 
estimate causal effects of maternal exposures on offspring birth weight were limited by an 
inability to adjust for fetal genotype in adequately-powered samples23, which can now be 
overcome by using WLM-adjusted estimates. We applied two-sample MR24 to estimate 
causal effects of maternal exposures on offspring birth weight, focusing on height, glycemic 
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traits and blood pressure. We selected SNPs known to be associated with each exposure, 
and regressed the WLM-adjusted maternal effects on birth weight for those SNPs against 
the effect estimates for the maternal exposure, weighting by the inverse of the variance of 
the maternal exposure effect estimates. In the same way, we used the WLM-adjusted fetal 
effects to estimate the casual effect of the offspring’s genetic potential on their own birth 
weight, and compared the results with the estimated maternal causal effects. 
 
Height and birth weight 
Classical animal experiments25 demonstrated that larger maternal size can support greater 
fetal growth. This is supported by observational human data showing that offspring height 
shifts from being closer to maternal than paternal height percentile in infancy towards mid-
parental height in adulthood, the latter reflecting the predominant role of inherited genetic 
variation26. However, several observational studies have provided mixed evidence regarding 
correlations between maternal or paternal height and offspring birth weight: some studies 
show a stronger correlation with maternal than paternal height27,28, which would be 
consistent with a role for intrauterine effects, while others show that maternal and paternal 
height are both strongly correlated with offspring birth weight29-31. The MR analysis, using 
693 height-associated SNPs32 (Supplementary Table 14), estimated that a 1 SD (6cm) higher 
maternal height is causally associated with a 0.11 SD (95%CI: 0.10, 0.13) higher offspring 
birth weight (Figure 3b), independent of the direct fetal effects. A similar estimate was 
obtained using the WLM-adjusted fetal effects on own birth weight (0.11 SD (95%CI: 0.09, 
0.13)), reflecting the role of inherited height alleles (Supplementary Table 15). Both a 
previous study33 and complementary analysis using transmitted and non-transmitted height 
alleles in mother-offspring pairs estimated a much larger contribution of direct fetal effects 
than indirect maternal effects to offspring birth weight (Supplementary Table 16, 
Methods), but with relatively small sample sizes. Contrary to a previous report33, there was 
little supportive evidence that the maternal height effect on birth weight was via prolonged 
gestation, (P=0.12; Supplementary Table 15). These MR results are consistent with the 
hypothesis that greater maternal height causally increases birth weight, and that this effect 
is independent of the direct birth weight-raising effect of height alleles inherited by the 
fetus. Although greater availability of space for fetal growth is a possible explanation, we 
cannot rule out other causal pathways. For example, causal associations between greater 
height and more favourable socio-economic position34 could enhance maternal nutritional 
status and result in higher offspring birth weight. We also cannot exclude the contribution 
of assortative mating35 to these results: correlation between maternal and paternal height 
genotypes could lead to similar maternal and fetal MR estimates.  
 
Glycemic traits and birth weight 
Maternal glucose is a key determinant of fetal growth: it crosses the placenta, stimulating 
the production of fetal insulin which promotes growth36, and as a consequence, strong, 
positive associations are seen between maternal fasting glucose, fetal insulin levels, and 
offspring birth weight37. In a randomized clinical trial of women with gestational diabetes 
mellitus, glucose control was shown to reduce offspring birth weight38. Therefore, we 
anticipated detecting a positive causal effect of maternal glucose on offspring birth weight, 
as previously observed using MR in a smaller sample23. Indeed, the MR analysis using 33 
fasting glucose-associated SNPs (Supplementary Table 14), estimated an 0.18 SD (95%CI: 
0.13, 0.23) higher offspring birth weight due to 1 SD (0.4mmol/L) higher maternal fasting 
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glucose, independent of the direct fetal effects (Supplementary Table 15, Figure 3c). A large 
part of the genetic variation underlying fasting glucose levels is implicated in pancreatic beta 
cell function and thus overlaps with the genetics of insulin secretion. To estimate the causal 
effect of insulin secretion on birth weight, we used 18 SNPs associated with disposition 
index, a measure of insulin response to glucose, adjusted for insulin sensitivity. Alleles that 
increase insulin secretion in the mother tend to decrease her glucose levels, which 
consequently reduces insulin-mediated growth of the fetus. This was reflected in the 
negative causal estimate from the MR analysis of the effect of maternal disposition index on 
offspring birth weight (-0.17 SD per 1 SD higher maternal disposition index (95%CI: -0.26, -
0.08); Supplementary Table 15). In contrast, we estimated that birth weight was 0.10 SD 
(95%CI: 0.02, 0.19) higher per 1 SD genetically higher fetal disposition index (Methods), 
highlighting that genetic variation underlying insulin secretion plays a key role in fetal 
growth, and suggesting that the genetic effects on disposition index are similar in fetal and 
adult life. 
 
Birth weight associations with previously-reported GWAS SNPs for fasting glucose, T2D, 
insulin secretion and insulin sensitivity loci were directionally consistent with the overall 
genetic correlations and supported the opposing contributions of fetal versus maternal 
glucose-raising alleles on birth weight (Supplementary Figures 11-14). Taken together with 
the WLM-adjusted genetic correlations, the MR results underline the importance of fetal 
insulin in fetal growth and demonstrate that fetal genetic effects link lower birth weight 
with reduced insulin secretion and higher T2D risk in later life6. However, further work is 
needed to investigate the role of maternal indirect genetic effects in the relationship 
between high birth weight and higher future risk of T2D.  
 
Blood pressure and birth weight 
Observational studies of the relationship between birth weight and later life blood pressure 
have produced mixed findings: some studies indicate that lower birth weight is associated 
with higher later life blood pressure and related comorbidities39, whereas others have 
shown that this relationship could be driven by a statistical artifact due to adjusting for 
current weight40,41. We have previously shown that genetic factors account for a large 
proportion of an association between lower birth weight and higher blood pressure5, but it 
was not clear whether this was due to direct fetal genotype effects, or indirect maternal 
effects, or a combination of the two. We explored this association further using several 
complementary analyses. The estimate of the birth weight-SBP covariance explained was 
higher when using the maternal genotyped SNP associations with offspring birth weight 
(65% (95%CI: 57, 74%)), than when using the fetal genotype associations with own birth 
weight (56% (95%CI: 48, 64%); Supplementary Table 17). A similar pattern was seen with 
the birth weight-diastolic blood pressure (DBP) covariance (maternal: 72% (95%CI: 58, 85%);  
fetal: 56% (95%CI: 46, 67%); Supplementary Table 17). Together with the larger maternal 
than fetal genetic correlation for SBP (Figure 2), these results point to the importance of 
indirect maternal effects of blood pressure on offspring birth weight (Supplementary 
Figures 15, 16). In line with this, MR analyses indicated that a 1SD (10mmHg) higher 
maternal SBP is causally associated with a 0.15 SD (95%CI: -0.19, -0.11) lower offspring birth 
weight, independent of the direct fetal effects. In contrast, there was no fetal effect of SBP 
on their own birth weight, after adjusting for the indirect maternal effect (-0.01 SD per 
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10mmHg, 95% CI: -0.05, 0.03; Figure 3d; Supplementary Tables 14, 15). Similar results were 
seen in the WLM-adjusted MR analyses of DBP on offspring and own birth weight. 
 
Estimating the causal effect of birth weight-lowering intrauterine exposures on offspring 
SBP 
A key question is whether maternal SNPs that reduce offspring birth weight through 
intrauterine effects are also associated with higher SBP in their adult offspring. Such an 
association would suggest that the maternal intrauterine effects cause the later SBP effect 
(i.e. through developmental adaptations) (Figure 4a, Supplementary Figure 17). To 
investigate this possibility, we tested the conditional association between maternal and 
offspring genetic scores for birth weight and offspring SBP as measured in 3,886 mother-
offspring pairs in the UK Biobank, with sensitivity analyses in 1,749 father-offspring pairs. 
The fetal genetic score for lower birth weight was associated with higher offspring SBP, even 
after adjustment for maternal (or paternal) birth weight genotypes. However, when 
adjusted for fetal genotypes, the maternal genetic score for lower birth weight was 
associated with lower (not higher) offspring SBP (Supplementary Table 18). Taken together, 
our results demonstrate that the observed negative correlation between birth weight and 
later SBP is driven by (i) the causal effect of higher maternal SBP on lower offspring birth 
weight (Figure 3d), in combination with (ii) the subsequent transmission of SBP-associated 
alleles to offspring, which then increase offspring SBP (Figure 4b), rather than by long-term 
developmental compensations to adverse in utero conditions.
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DISCUSSION 
 
In greatly-expanded GWAS and follow-up analyses of own and offspring birth weight, we 
have identified 129 novel association signals and partitioned the genetic effects on birth 
weight into direct fetal and indirect maternal (intrauterine) effects. Using these partitioned 
effects, we identified fetal- and maternal-specific mechanisms and tissues involved in the 
regulation of birth weight, and mechanisms with directionally-opposing effects in the fetus 
and mother (e.g. insulin secretion, fasting glucose). 
 
MR analyses using the WLM-adjusted estimates showed (i) both direct fetal and indirect 
maternal effects of height-raising genotypes contribute to higher offspring birth weight, (ii) 
fetal, and not maternal, genotype effects explain the negative genetic correlation between 
birth weight and later T2D, and (iii) the negative genetic correlation between birth weight 
and adult SBP is the result of both indirect SBP-raising effects of maternal genotypes 
reducing offspring birth weight, and direct effects of fetal genotypes on higher adult SBP. 
The resolution of maternal vs. fetal effects was higher in these MR analyses than has 
previously been achieved using analyses of available mother-child pairs23, due to greater 
statistical power. Recently, a number of studies have attempted to use MR methodology to 
investigate causal links between birth weight and later T2D43-45. However, such naïve MR 
analyses using two-sample approaches in unrelated sets of individuals, which do not 
properly account for the correlation between maternal and fetal genotype effects, may 
result in erroneous conclusions regarding causality. Future investigations into causal links 
between birth weight and later T2D or other disease outcomes will require larger samples 
than are currently available, with maternal and offspring genotypes and offspring later life 
disease outcomes. 
 
There are some limitations to this study (see Supplementary Note for a full discussion). 
First, the MR results concern birth weight variation within the normal range and do not 
necessarily reflect the effects of extreme environmental events (e.g. famine), which may 
exert qualitatively different effects. Additionally, we have assumed a linear relationship 
between birth weight and later life traits, which may be an oversimplification for some traits 
such as T2D. Second, birth weight is the end marker of a developmental process, with 
critical periods during the process that may make the fetus particularly sensitive to 
environmental influences. The MR analyses could therefore be masking effects at certain 
critical periods. Third, we have assumed that genetic variants identified in large GWAS of 
SBP and glycemic traits in males and non-pregnant females are similarly associated in 
pregnant women. Fourth, we have not investigated the potential gender difference in the 
associations between birth weight and later life traits. Fifth, we have assumed that the 
critical period of exposure to maternal indirect genetic effects is pregnancy, and that the 
estimates do not reflect pre-pregnancy effects on primordial oocytes or post-natal effects42. 
Sixth, we have not considered paternal genotypes, and it is possible that this omission has 
biased the results of some of our analyses. Finally, although we were able to fit the full SEM 
at the 209 lead SNPs, we were unable to fit the SEM, including the two degree of freedom 
test (i.e. where maternal and fetal paths are constrained to zero), at all SNPs across the 
genome.  
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To conclude, the systematic separation of fetal from maternal genetic effects in a well-
powered study has enhanced our understanding of the regulation of birth weight and of its 
links with later cardio-metabolic health. In particular, we show that the association between 
lower birth weight and higher adult blood pressure is attributable to genetic effects, and not 
to intrauterine programming. In successfully separating fetal from maternal genetic effects 
and using them in Mendelian randomization analyses, this work sets a precedent for future 
studies seeking to understand the causal role of the intrauterine environment in later life 
health.
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ONLINE METHODS 
 
Ethics statement 
All human research was approved by the relevant institutional review boards and conducted 
according to the Declaration of Helsinki. Participants of all studies provided written 
informed consent. The UK Biobank has approval from the North West Multi-Centre 
Research Ethics Committee (MREC), which covers the UK. Ethical approval for the ALSPAC 
study was obtained by the ALSPAC Ethics and Law Committee and the local Research Ethics 
Committees. Ethical approval for the EFSOCH study was given by the North and East Devon 
Local Ethics Committee. Approval for access to data and biological material for MoBa-
HARVEST was granted by the Scientific Management Committee of MoBa and the Regional 
Committee for Medical and Health Research Ethics. 
 
Statistical tests 
Details of statistical tests used in the various analyses are reported under the appropriate 
headings below. All tests were two-sided, unless otherwise stated. 
 
GWAS of own birth weight 
European ancestry meta-analysis: The European ancestry GWAS meta-analysis of own birth 
weight consisted of two components (Supplementary Figure 1): (i) 80,745 individuals from 
35 studies participating in the EGG Consortium from Europe, USA and Australia; and (ii) 
217,397 individuals of white European origin from the UK Biobank (see Supplementary 
Note for details on phenotype preparation and GWAS analyses). We combined the 
summary statistics from the EGG meta-analysis with the UK Biobank summary statistics 
using a fixed-effects meta-analysis in GWAMA46 (max N=297,142). Variants failing GWAS 
quality control filters, reported in less than 50% of the total sample size in the EGG 
component, or with MAF<0.1%, were excluded. We also performed a fixed-effects meta-
analysis of the association summary statistics for 16,095 directly genotyped SNPs on the X-
chromosome from the UK Biobank and the EGG meta-analysis using GWAMA46 (max 
N=270,929). Genome-wide significance was defined as P<6.6x10-9 as calculated by Kemp et 
al.47, which was similar to the thresholds calculated using permutations by Jones el al.48. A 
locus was defined as one or more SNPs reaching genome-wide significance within a region 
of the genome; two genome-wide significant SNPs are defined as belonging to two separate 
loci if the distance between them is ≥500kb. The lead SNP within each locus was the SNP 
with the smallest P-value. 
Several sensitivity analyses were conducted to confirm the quality of our meta-analysis 
results (see Supplementary Note for details). Univariate LD score regression49 estimated the 
genomic inflation as 1.08, indicating that the majority of genome-wide inflation of the test 
statistics was due to polygenicity. To assess the impact of this inflation, we re-calculated the 
association P-values after adjusting the test statistics for the LD score regression intercept 
(Supplementary Table 5). 
 
Approximate conditional and joint multiple-SNP (COJO) analysis to identify additional 
independent signals: Approximate COJO analysis13 was performed in GCTA50 using the 
European ancestry meta-analysis summary statistics to identify independent association 
signals attaining genome-wide significance (P<6.6x10-9). The LD reference panel was made 
up of 344,246 unrelated UK Biobank participants defined by the UK Biobank as having 
 23 
British ancestry and SNPs were restricted to those present in the HRC reference panel. At 
each locus, only SNPs labelled by GCTA as “independent” and not in LD with the original 
lead SNP (R2<0.05) were listed as secondary SNPs. 
 
Trans-ethnic meta-analysis: To identify any further independent birth weight-associated 
SNPs, we conducted a trans-ethnic meta-analysis combining three components 
(Supplementary Figure 1): (i) 80,745 individuals from the European ancestry component 
within EGG; (ii) 12,948 individuals from nine studies within EGG from diverse ancestry 
groups: African American, Afro-Caribbean, Mexican, Chinese, Thai, Filipino, Surinamese, 
Turkish and Moroccan; and (iii) 227,530 individuals of all ancestries from the UK Biobank. 
The same strategy and variant filtering criteria were applied as in the European meta-
analysis (Supplementary Figure 1). Univariate LD score regression49 estimated the genomic 
inflation as 1.08. P-values after adjustment of the test statistics for the LD score regression 
intercept are presented in Supplementary Table 5. 
 
GWAS of offspring birth weight 
European ancestry meta-analysis: The European ancestry GWAS meta-analysis of offspring 
birth weight consisted of three components (Supplementary Figure 2): (i) 12,319 individuals 
from 10 European GWAS imputed up to the HapMap 2 reference panel; and (ii) 7,542 
individuals from two European GWAS imputed up to the HRC panel; and (iii) 190,406 
individuals of white European origin from the UK Biobank (see Supplementary Note for 
details on phenotype preparation and GWAS analyses). We conducted a European ancestry 
fixed-effects meta-analysis to combine the association summary statistics from the three 
components using GWAMA46 (max N=210,267). We also performed a fixed-effects meta-
analysis of the association summary statistics for 18,137 directly genotyped SNPs on the X-
chromosome from the UK Biobank and the EGG meta-analysis using GWAMA46 (max 
N=197,093). The same strategy and variant filtering criteria were applied as in the meta-
analysis of own birth weight and the same sensitivity analyses were conducted 
(Supplementary Note).  
Univariate LD score regression49 estimated the genomic inflation as 1.05. We recalculated 
the P-values after adjusting the test statistics for this LD score intercept (Supplementary 
Table 5). 
 
Approximate COJO analysis to identify additional independent signals: We performed 
approximate COJO analysis13 using the European ancestry meta-analysis summary statistics 
of offspring birth weight, using the same reference panel as in the own birth weight analysis 
and listed any secondary “independent” SNPs associated with offspring birth weight. 
 
Trans-ethnic meta-analysis: We conducted a trans-ethnic meta-analysis combining three 
components (Supplementary Figure 2): (i) 12,319 individuals from 10 European GWAS 
imputed up to the HapMap 2 reference panel; and (ii) 7,542 individuals from two European 
GWAS imputed up to the HRC panel; and (iii) 210,208 individuals of all ancestry from the UK 
Biobank. The same strategy and variant filtering criteria were applied as in the European 
meta-analysis (Supplementary Figure 2) and the same sensitivity analyses were conducted 
(Supplementary Material). Univariate LD score regression49 estimated the genomic inflation 
as 1.04 and the recalculated P-values after adjusting the test statistics for this LD score 
intercept are presented in Supplementary Table 5. 
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Colocalization methods 
For each signal where we identified different lead SNPs in the GWAS of own birth weight 
and offspring birth weight, we performed co-localization analysis using the "coloc" R 
package51. For each signal, we input the regression coefficients, their variances and SNP 
minor allele frequencies for all SNPs 500kb up and downstream of the lead SNP from the 
European meta-analysis. We used the coloc.abf() function, with its default parameters, to 
calculate posterior probabilities that the own birth weight and offspring birth weight lead 
SNPs were independent (H3) or shared the same associated variant (H4). We called variants 
the same signal if the H4 posterior probability was greater than 0.50, and different signals if 
the H3 posterior probability was greater than 0.50.  
 
Estimation of genetic variance explained 
Firstly, we estimated the proportion of birth weight variance explained by fetal genotypes, 
maternal genotypes and the covariance between the two at the 190 genome-wide 
significant signals in the Norwegian Mother and Child Cohort Study (MoBa-HARVEST; 
https://www.fhi.no/en/studies/moba/). This sample was independent of samples 
contributing to the discovery meta-analyses, apart from a small potential overlap with 
mothers from the MoBa-2008 sample that was included in the GWAS of offspring birth 
weight (<0.07% of the meta-analysis sample). For the 19 signals that had different maternal 
and fetal lead SNPs, the fetal SNP (and not the maternal SNP) was used in the analysis to 
avoid collinearity in the model. We excluded multiple births, babies of non-European 
descent, born before 37 weeks of gestation, born with a congenital anomaly or still-born. 
Birth weight was Z-score transformed and all models were adjusted for sex, gestational 
duration and the first 4 ancestry informative principal components. We conducted a linear 
regression analysis in R52 using 13,934 mother-offspring pairs where offspring birth weight 
was regressed on the maternal and fetal genotypes at all 190 SNPs simultaneously. The 
proportion of variance explained by fetal genotypes at the 190 genome-wide significant 
signals was calculated as: !2𝑝$(1 − 𝑝$)𝛽*+,-𝑣𝑎𝑟(𝐵𝑊)345$63  
Where pi is the effect allele frequency of the ith SNP, 𝛽*+,  is the regression coefficient for the 
effect of the offspring’s genotype at the ith SNP on offspring birth weight and var(BW) is the 
variance of offspring birth weight (which is approximately 1 as birth weight was Z-score 
transformed). A similar formula was used to calculate the variance explained by maternal 
genotypes, using : !2𝑝$(1 − 𝑝$)𝛽*7,-𝑣𝑎𝑟(𝐵𝑊)345$63  
Where 𝛽*7,  is the regression coefficient for the effect of the maternal genotype at the ith 
SNP on offspring birth weight. The following formula was used to calculate twice the 
covariance: !2𝑝$(1 − 𝑝$)𝛽*+,𝛽*7,𝑣𝑎𝑟(𝐵𝑊)345$63  
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Secondly, we used maternal genome-wide complex trait analysis11 (M-GCTA) to estimate 
the proportion of variance explained in birth weight by genome-wide SNPs, or SNPs they 
tag, in the fetal genome, the maternal genome, the covariance between the two or 
environmental factors in MoBa-HARVEST. The same phenotype was used as in the previous 
analysis and the model was adjusted for sex and gestational duration. Mothers or offspring 
were excluded if they were related to others in the sample, using a genetic relationship cut-
off 0.025, leaving N=7,910 mother-offspring pairs available for analysis. 
 
Identifying eQTL linked genes 
We used FUSION53 with the v6p release of the GTEx data14 to identify eQTL linked genes. 
FUSION incorporates information from gene-expression and GWAS data to translate 
evidence of association with a phenotype from the SNP-level to the gene. Only gene level 
results from the adjusted model were taken forward for consideration. Each of the genes 
implicated by this analysis survived multiple testing correction (Bonferroni corrected 
P<6x10-7, after adjusting for 44 tissues) and were independent from other proximal genes 
tested in a joint model. 
 
Placenta eQTL look ups 
We annotated genome-wide significant birth weight-associated SNPs with gene expression 
data (200/209 SNPs available) from European ancestry placental samples in the Rhode 
Island Child Health Study15 (RICHS; N=123 with fetal genotype, including 71 with birth 
weight appropriate for gestational age, 15 small for gestational age, and 37 large for 
gestational age). SNPs were annotated if they had genome-wide empirical FDR<0.01 for 
association with one or more transcripts and r2>0.7 with a lead eQTL SNP. 
 
TAD pathways 
Topologically associating domains (TAD) pathway analysis was performed using software 
described in Way et al.16. Briefly, the software uses publicly available TAD boundaries, 
identified in human embryonic stem cells and fibroblasts using a Hidden Markov Model17, to 
prioritize candidate genes at GWAS SNPs. These TAD boundaries are stable across different 
cell types and can be used to identify genomic regions where non-coding causal variants will 
most likely impact tissue-independent function. 
 
Structural equation model for estimating adjusted maternal and fetal effects of the 
genome-wide significant variants 
The structural equation modelling (SEM) approach used to estimate adjusted maternal and 
fetal effects has been described elsewhere12 (for additional details, see Supplementary 
Note).  
The SEM was fit to data from 146 genome-wide significant lead fetal SNPs and 72 lead 
maternal SNPs from the GWAS meta-analysis (Supplementary Figure 4). In order to identify 
a subset of unrelated individuals in the UK Biobank (as the SEM cannot easily account for 
relatedness), we generated a genetic relationship matrix in the GCTA software package50 
(version 1.90.2) and excluded one of every pair of related individuals with a genetic 
relationship greater than 9.375%. After the same exclusions were made as in the GWAS, 
85,518 unrelated individuals of European ancestry with their own and their offspring’s birth 
weight, 98,235 individuals with their own birth weight only, and 73,981 with their 
offspring’s birth weight only were available for analysis. We fit linear regression models to 
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birth weight and offspring birth weight in this subset of unrelated, European ancestry 
individuals adjusting for sex (own birth weight only), assessment centre and the top 40 
ancestry informative principal components provided by the UK Biobank to account for any 
remaining population substructure. The residuals from these regression models were Z-
score transformed for analysis. Because we included the summary statistics from the meta-
analysis of the EGG studies, rather than the individual level data, we were unable to account 
for the small subset individuals who contributed to both the own birth weight and offspring 
birth weight GWAS meta-analyses. Based on the results from simulations (not shown), we 
expect that this non-independence will result in very slightly smaller standard errors and 
increased type 1 error rate, particularly for the fetal effect which is estimated from a larger 
sample size than was available to estimate the maternal effect. Therefore, we conducted a 
sensitivity analysis that first excluded EGG studies from the meta-analysis of own birth 
weight that contributed to both GWAS meta-analyses of own and offspring birth weight 
(e.g. ALSPAC), and then refitted the non-overlapping data in the SEM; these results are 
presented in Supplementary Table 19. For SNPs identified on the X chromosome, we fit a 
slightly different SEM due to males having double the expected genetic variance at X linked 
loci compared to females. We did not incorporate summary statistics from the EGG 
consortium as the GWAS results were not stratified according to sex (additional details on 
the X chromosome analysis are provided in the Supplementary Note and Supplementary 
Figure 6b). 
We used the estimates from the SEM to classify the lead SNPs into the following five 
categories; 1) fetal only: the 95% confidence interval surrounding the fetal effect estimate 
does not overlap zero and does not overlap the 95% confidence interval around the 
maternal effect estimate. Additionally, the 95% confidence interval surrounding the 
maternal effect estimate overlaps zero; 2) maternal only: the 95% confidence interval 
surrounding the maternal effect estimate does not overlap zero and does not overlap the 
95% confidence interval around the fetal effect estimate. Additionally, the 95% confidence 
surrounding the fetal effect estimate overlaps zero; 3) fetal and maternal, effects going in 
the same direction: the 95% confidence intervals around both the maternal and fetal effect 
estimates do not overlap zero, and their effect is in the same direction; 4) fetal and 
maternal, effects going in opposite direction: the 95% confidence intervals around both the 
maternal and fetal effect estimates do not overlap zero, and their effects are in opposite 
directions; and 5) unclassified: SNPs that do not fall into any of these categories, and 
therefore the 95% confidence intervals around the maternal and fetal effect estimates 
overlap, and at least one overlaps zero. 
 
Meta-analysis of maternal and fetal effects from a conditional regression analysis in 
mother-offspring pairs 
We conducted conditional association analyses for all 209 lead SNPs in 18,873 mother-
offspring pairs from three studies (MoBa-HARVEST, ALSPAC and EFSOCH) adjusting for both 
maternal and offspring genotype and combined the summary statistics for each SNP in a 
fixed effects meta-analysis using METAL54. We compared the estimates of the maternal and 
fetal effects of this meta-analysis to the SEM-adjusted maternal and fetal effects using a 
heterogeneity test (Supplementary Table 6). 
 
Approximation of the SEM for genome-wide analyses 
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The SEM is computationally intensive to fit, making it difficult to run on all SNPs across the 
genome. Therefore, we developed an approximation of the SEM using a linear 
transformation and ordinary least squares linear regression, which we refer to as the 
weighted linear model adjusted (WLM-adjusted) analyses. The full details of the derivation 
are provided in the Supplementary Note. Briefly, from ordinary least squares regression we 
know that the estimated fetal effect size from the GWAS of own birth weight, 𝛽*+89:;<, is 
calculated by dividing the sample covariance between birth weight and SNP by the sample 
variance of the SNP. Similarly, the estimated maternal effect from the GWAS of offspring 
birth weight, 𝛽*789:;<, is calculated by dividing the sample covariance between offspring 
birth weight and SNP by the sample variance of the SNP. It follows that an estimate of the 
fetal effect adjusted for the maternal genotype is (see Supplementary Note for full 
derivation): 𝛽*+:;< = −23𝛽*789:;< + 43𝛽*+89:;<  
and an estimate of the maternal effect adjusted for the fetal genotype is: 𝛽*7:;< = 43𝛽*789:;< − 23𝛽*+89:;<  
If the model is truly linear, then the same estimates can be obtained by transforming the 
reported birth weights rather than the regression coefficients55. See the Supplementary 
Note and Supplementary Figure 18 for a flow diagram of the full analysis pipeline. A 
comparison of the results using this WLM method and the full SEM for the lead SNPs is 
presented in Supplementary Figure 9. 
 
Gene expression integration 
To identify which tissue types were most relevant to genes involved in birth weight, we 
applied LD score regression to specifically expressed genes (“LDSC-SEG”)19. We used the 
summary statistics from the GWAS meta-analysis of own and offspring birth weight and the 
WLM-adjusted meta-analyses. Briefly, the method takes each tissue, ranking genes by a t-
statistic for differential expression, using sex and age as covariates, and excluding all 
samples in related tissues. It then takes the top 10% of ranked genes, and makes a genome 
annotation including these genes (exons and introns) plus 100kb on either side. Finally, it 
uses stratified LD score regression to estimate the contribution of this annotation to per-
SNP birth weight heritability, adjusting for all categories in the baseline model. We 
computed significance using a block jackknife over SNPs, and corrected for the number of 
tissues tested. 
 
Gene-set enrichment analysis (MAGENTA) 
Pathway-based associations using summary statistics from the GWAS meta-analysis of own 
and offspring birth weight and WLM-adjusted meta-analysis were tested using MAGENTA56. 
Briefly, the software maps each gene to the SNP with the lowest P-value within a 110kb 
upstream and 40kb downstream window. This P-value is corrected for factors such as SNP 
density and gene size using a regression model. Genes within the HLA region were excluded. 
The observed number of gene scores within a given pathway with a ranked gene score 
above a given threshold (95th or 75th percentile) was calculated. This statistic was compared 
with 1,000,000 randomly permuted pathways of the same size to calculate an empirical P-
value for each pathway. We considered pathways with false discovery rate (FDR) < 0.05 to 
be of interest. The 3,230 biological pathways tested were from the BIOCARTA, Gene 
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Ontology, KEGG, PANTHER and READTOME databases along with a small number of custom 
gene-sets. 
 
Gestational duration associations 
We extracted the 209 lead birth weight-associated SNPs from the summary statistics 
provided by 23andMe and published in a recent GWAS of gestational duration20. Any birth 
weight-associated SNP that was also associated with gestational duration (P<2.4x10-4, 
corrected for 209 tests) was followed-up in 13,206 mother-child pairs from the MoBa-
HARVEST, ALSPAC and EFSOCH studies. Preterm births (gestational duration <37 weeks) 
were removed before analysis, and gestational duration and birth weight were both z-score 
transformed. We conducted linear regression analyses to test the association between 
maternal or fetal genotype (both unadjusted and adjusted genotype effects) and gestational 
duration, birth weight or gestational duration adjusted for birth weight. The association 
analysis results were combined using inverse variance weighted meta-analysis. We also 
combined the unadjusted maternal SNP-gestational duration associations with the 
23andMe summary statistics20 using P value based meta-analysis implemented in METAL54. 
 
Association between birth weight-associated SNPs and a variety of traits  
We performed GWAS on 78 traits in the UK Biobank using BOLT-LMM in an analogous way 
to analysis of own birth weight. Phenotype definitions for the 78 traits are described in 
Frayling et al.57. Association statistics for the 209 lead birth weight-associated SNPs were 
then extracted from the results (Supplementary Table 13). Additionally, we searched the 
NHGRI GWAS catalog (https://www.ebi.ac.uk/gwas/; accessed 16th January 2018) for the 
209 lead birth weight-associated SNPs, or SNPs in high LD with the 209 lead SNPs (r2>0.8), 
and reported associations with other traits (Supplementary Table 13). 
 
Linkage-Disequilibrium (LD) score regression 
LD score regression, which has been described in detail elsewhere18, was used to estimate 
the genetic correlation between birth weight and a range of traits/diseases. We used 
LDHub58 (ldsc.broadinstitute.org/) to perform the LD score regression analyses. Due to the 
different LD structure across ancestry groups, the summary statistics from the European 
only birth weight analyses were uploaded to LDHub and genetic correlations were 
calculated with all available phenotypes. We conducted four separate analyses in LDHub 
using: (1) GWAS meta-analysis of own birth weight, (2) GWAS meta-analysis of offspring 
birth weight, (3) WLM-adjusted fetal effect and (4) WLM-adjusted maternal effect. 
To calculate the genetic correlation between the maternal and fetal effect estimates from 
the unadjusted and WLM-adjusted analyses, and also between gestational duration and the 
WLM-adjusted maternal and fetal effects, we used the scripts provided by the developer 
(https://github.com/bulik/ldsc). 
 
Mendelian randomization analyses of maternal and fetal exposures on offspring birth 
weight 
Two-sample Mendelian randomization analyses were performed with own or offspring birth 
weight as outcomes. The exposures included height, fasting glucose, disposition index of 
insulin secretion59, insulin sensitivity and systolic (SBP) and diastolic blood pressure (DBP). 
The SNP-exposure associations were taken from external studies (Supplementary Table 14). 
The SNP-outcome associations were taken from the current European GWAS meta-analyses 
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of own birth weight, offspring birth weight, WLM-adjusted fetal effect and WLM-adjusted 
maternal effect. Two-sample Mendelian randomization regresses effect sizes of SNP-
outcome associations against effect sizes of SNP-exposure associations, with an inverse-
variance weighted (IVW) analysis, giving similar results to the two-stage least squares 
analysis in a single sample60. We performed several sensitivity analyses to assess the impact 
of genetic pleiotropy on the causal estimates including MR-Egger61, Weighted Median 
(WM)62 and Penalized Weighted Median (PWM)62 (see Supplementary Table 15 for results). 
Details of the R code for the MR analyses are provided elsewhere61,62 . 
Due to the strong negative correlation between estimates of the maternal and fetal genetic 
effects on birth weight, we conducted simulations to confirm that this correlation did not 
bias the results of downstream MR analyses; these simulations are described in the 
Supplementary Note. 
 
Transmitted/non-transmitted allele scores in ALSPAC 
Allelic transmission was determined for 4,962 mother/offspring pairs in ALSPAC. We first 
converted maternal and fetal genotypes into best guess genotypes where SNPs of interest 
had been imputed. Where one or both of the mother/offspring pair were homozygous, 
allelic transmission is trivial to determine. Where both mother and offspring were 
heterozygous for the SNP of interest we used phase imputation generated using SHAPEIT263 
to examine the haplotypes in the region of the SNP of interest to determine allelic 
transmission. Weighted allele scores were generated for maternal non-transmitted, shared 
(maternal transmitted) and paternally inherited fetal alleles for SBP, DBP, fasting glucose, 
insulin secretion and insulin sensitivity. Associations were tested between the weighted 
allele scores and birth weight. 
 
Covariance between birth weight and adult traits explained by genotyped SNPs 
The genetic and residual covariance between birth weight and several quantitative/disease 
phenotypes was calculated in the UK Biobank using REML in BOLT-LMM64 . We included 
215,444 individuals of European ancestry with data on own birth weight and 190,406 with 
data on offspring birth weight. SNPs with minor allele frequency < 1%, evidence of deviation 
from Hardy-Weinberg equilibrium (P≤1x10-6) or overall missing rate > 0.015 were excluded, 
resulting in 524,307 genotyped SNPs for analysis. Ninety-five per cent confidence intervals 
for the proportion of covariance explained by genotyped variants were calculated as 
gcov/(gcov+rcov) ± 1.96*gcovSE/abs(gcov+rcov) where gcov is genetic covariance, rcov is 
residual covariance, gcovSE is the standard error for gcov and abs is the absolute value. 
Details of the phenotype preparation for the adult traits is provided in the Supplementary 
Note. 
 
Association between maternal SNPs associated with offspring birth weight and later life 
offspring systolic blood pressure 
Using the UK Biobank, we tested whether maternal SNPs associated with offspring birth 
weight were also associated with offspring SBP in later life. The UK Biobank released kinship 
information generated in KING65, which included kinship coefficients and IBS0 estimates. We 
defined parent/offspring pairs using the kinship coefficient and IBS0 cut-offs recommended 
in Manichaikul et al.65. There were 5,635 unique parent/offspring pairs of European ancestry 
with SBP data (for parents who had multiple offspring with SBP data, only the oldest 
offspring was included in the analysis); 3,886 mother/offspring pairs and 1,749 
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father/offspring pairs. We tested the relationship between unweighted allelic scores of birth 
weight-associated SNPs in mothers/fathers and offspring SBP (see Supplementary Note for 
SBP phenotype preparation) before and after adjusting for offspring genotypes at the same 
loci. We examined unweighted allelic scores consisting of all autosomal lead birth weight-
associated SNPs available in the UK Biobank (205 SNPs), 72 autosomal SNPs that showed 
evidence of a maternal effect, and 31 autosomal SNPs that showed evidence only of 
maternal effects on birth weight. We also looked at the SNPs previously associated with SBP 
(Supplementary Table 14) as a sensitivity analysis to rule out the possibility of postnatal 
pleiotropic effects contaminating our results. All analyses were adjusted for offspring age at 
SBP measurement, sex and assessment center. 
 
Reporting Summary 
Further information on research design is available in the Nature Research Reporting 
Summary linked to this article 
 
Data availability 
The genotype and phenotype data are available upon application from the UK Biobank 
(http://www.ukbiobank.ac.uk/). Individual cohorts participating in the EGG consortium 
should be contacted directly as each cohort has different data access policies. GWAS 
summary statistics from this study are available via the EGG website (https://egg-
consortium.org/). 
 
Code availability 
Custom written code is available upon request from the first author. 
 
References 
46 Magi, R. & Morris, A. P. GWAMA: software for genome-wide association meta-
analysis. BMC bioinformatics 11, 288, doi:10.1186/1471-2105-11-288 (2010). 
47 Kemp, J. P. et al. Identification of 153 new loci associated with heel bone mineral 
density and functional involvement of GPC6 in osteoporosis. Nat Genet 49, 1468-
1475, doi:10.1038/ng.3949 (2017). 
48 Jones, S. E. et al. Genome-wide association analyses of chronotype in 697,828 
individuals provides insights into circadian rhythms. Nature Communications 10, 343, 
doi:10.1038/s41467-018-08259-7 (2019). 
49 Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from 
polygenicity in genome-wide association studies. Nat Genet 47, 291-295, 
doi:10.1038/ng.3211 
http://www.nature.com/ng/journal/v47/n3/abs/ng.3211.html#supplementary-information 
(2015). 
50 Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide 
complex trait analysis. American journal of human genetics 88, 76-82, 
doi:10.1016/j.ajhg.2010.11.011 (2011). 
51 Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic 
association studies using summary statistics. PLoS Genet 10, e1004383, 
doi:10.1371/journal.pgen.1004383 (2014). 
52 Ihaka, R., Gentleman R. R: a language for data analysis and graphics. Journal of 
Computational and Graphical Statistics 5, 299-314 (1996). 
 31 
53 Gusev, A. et al. Integrative approaches for large-scale transcriptome-wide 
association studies. Nat Genet 48, 245-252, doi:10.1038/ng.3506 (2016). 
54 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of 
genomewide association scans. Bioinformatics (Oxford, England) 26, 2190-2191, 
doi:10.1093/bioinformatics/btq340 (2010). 
55 Mardia, K. V. Multivariate analysis / K.V. Mardia, J.T. Kent, J.M. Bibby.  (Academic 
Press, 1979). 
56 Segre, A. V., Groop, L., Mootha, V. K., Daly, M. J. & Altshuler, D. Common inherited 
variation in mitochondrial genes is not enriched for associations with type 2 diabetes 
or related glycemic traits. PLoS Genet 6, doi:10.1371/journal.pgen.1001058 (2010). 
57 Frayling, T. M. et al. A Common Allele in FGF21 Associated with Sugar Intake Is 
Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood 
Pressure. Cell reports 23, 327-336, doi:10.1016/j.celrep.2018.03.070 (2018). 
58 Zheng, J. et al. LD Hub: a centralized database and web interface to perform LD score 
regression that maximizes the potential of summary level GWAS data for SNP 
heritability and genetic correlation analysis. Bioinformatics (Oxford, England), 
doi:10.1093/bioinformatics/btw613 (2016). 
59 Prokopenko, I. et al. A central role for GRB10 in regulation of islet function in man. 
PLoS Genet 10, e1004235, doi:10.1371/journal.pgen.1004235 (2014). 
60 Burgess, S., Scott, R. A., Timpson, N. J., Davey Smith, G. & Thompson, S. G. Using 
published data in Mendelian randomization: a blueprint for efficient identification of 
causal risk factors. European journal of epidemiology 30, 543-552, 
doi:10.1007/s10654-015-0011-z (2015). 
61 Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid 
instruments: effect estimation and bias detection through Egger regression. 
International journal of epidemiology 44, 512-525, doi:10.1093/ije/dyv080 (2015). 
62 Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in 
Mendelian Randomization with Some Invalid Instruments Using a Weighted Median 
Estimator. Genetic epidemiology 40, 304-314, doi:10.1002/gepi.21965 (2016). 
63 Delaneau, O., Zagury, J. F. & Marchini, J. Improved whole-chromosome phasing for 
disease and population genetic studies. Nature methods 10, 5-6, 
doi:10.1038/nmeth.2307 (2013). 
64 Loh, P. R. et al. Efficient Bayesian mixed-model analysis increases association power 
in large cohorts. Nat Genet 47, 284-290, doi:10.1038/ng.3190 (2015). 
65 Manichaikul, A. et al. Robust relationship inference in genome-wide association 
studies. Bioinformatics (Oxford, England) 26, 2867-2873, 
doi:10.1093/bioinformatics/btq559 (2010). 
 32 
Figures: 
 
Figure 1: Structural equation modelling (SEM)-adjusted fetal and maternal effects for the 
193 lead SNPs that were identified in the GWAS of either own birth weight (left panel) or 
offspring birth weight (right panel) with minor allele frequency greater than 5%. The SEM 
included 85,518 individuals from the UK Biobank with both their own and offspring’s birth 
weight, 178,980 and 93,842 individuals from the UK Biobank and the EGG consortium with 
only their own birth weight or offspring’s birth weight respectively. The colour of each point 
indicates the SEM-adjusted fetal effect on own birth weight association P-value and the 
shape of each point indicates the SEM-adjusted maternal effect on offspring birth weight 
association P-value. P-values for the fetal and maternal effect were calculated using a two-
sided Wald test. SNPs which are labelled with the name of the closest gene are those which 
were identified in the GWAS of own birth weight but whose effects are mediated through 
the maternal genome (left panel) and SNPs that were identified in the GWAS of offspring 
birth weight but whose effects are mediated through the fetal genome (right panel). SNPs 
are aligned to the birth weight increasing allele from the GWAS. 
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Figure 2: Genome-wide genetic correlation between birth weight and a range of traits and 
diseases in later life. Genetic correlation (rg) and corresponding 95% confidence intervals 
between birth weight and the traits were estimated using linkage disequilibrium (LD) score 
regression in LD Hub. Genetic correlations were estimated from the summary statistics of 
the weighted linear model (WLM)-adjusted fetal genome-wide association study (GWAS; 
WLM-adjusted fetal effect on own birth weight) and the WLM-adjusted maternal GWAS 
(WLM-adjusted maternal effect on offspring birth weight). The total sample size included in 
the WLM-adjusted GWAS is 406,063 individuals with their own and/or their offspring’s birth 
weight. The genetic correlation estimates are colour coded according to their intensity and 
direction (red for positive correlation and blue for negative correlation). HOMA-B/IR, 
homeostasis model assessment of beta-cell function/insulin resistance; HbA1c, hemoglobin 
A1c; ADHD, attention deficit hyperactivity disorder. See Supplementary Table 10 for the 
references for each of the traits and diseases displayed and the genetic correlation results 
for other traits and diseases. 
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Figure 3. Mendelian randomization (MR) to assess the causal effect of maternal 
intrauterine exposures on offspring birth weight (adapted from Lawlor et al. 44) 
a. Since maternal and fetal genotypes are correlated, it is essential to account for offspring 
genotype in this analysis. The continuous, thin arrow represents the relationship between 
the genetic instrument and intrauterine exposure. The dashed arrows represent potential 
confounding via maternal characteristics which, under MR assumptions, are not associated 
with the genetic instrument. The dotted arrows represent potential violation of MR 
assumptions via offspring genotype. The thick arrow represents the causal effect of interest. 
 
b. Higher offspring birth weight is caused by direct fetal genetic effects of height-raising 
alleles and indirect effects of maternal height-raising alleles. Maternal indirect effects of 
height-raising alleles may increase offspring birth weight by increasing the space available 
for growth, but we cannot rule out alternative explanations e.g. assortative mating. 
 
c. Higher maternal fasting glucose levels increase offspring birth weight. Conversely, direct 
fetal genetic effects of glucose-raising alleles reduce birth weight. This is likely due to their 
effects on insulin: variants that lower maternal insulin levels increase maternal glucose, 
which crosses the placenta and stimulates fetal insulin-mediated growth. However, the 
same variants in the fetus cause lower fetal insulin levels, and consequently, reduced fetal 
insulin-mediated growth. 
 
d. Higher maternal SBP is causally associated with lower offspring birth weight. After 
adjusting for maternal effects, there was no evidence of an effect of offspring’s own SBP 
genetic score on their own birth weight. 
 
SEP, socio-economic position; BW, birth weight; FPG, fasting plasma glucose; SBP, systolic 
blood pressure. 1 SD of BW = 484g9,42 
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Figure 4. Mendelian randomization (MR) to assess the causal effect of intrauterine growth 
on offspring adult outcomes, using maternal intrauterine exposures that influence fetal 
growth. 
a. Maternal genotype should be associated with offspring birth weight independently of 
offspring genotype, so it is essential to adjust the analysis for offspring genotype. 
The continuous, thin, arrow represents the relationship between the genetic instrument 
and intrauterine exposure. The long-dashed arrows denote the (maternal and possibly fetal) 
genotype associations with birth weight; these arrows highlight the assumption that genetic 
variation influences offspring adult outcome via intrauterine growth, not birth weight. The 
short-dashed arrows represent potential confounding via maternal and offspring 
characteristics. The dotted arrow represents potential violation of assumptions of the MR 
analysis via offspring genotype. The thick arrow represents the causal effect of interest. 
We have not estimated the size of the causal effect as we do not have effect estimates for 
the SNP-maternal intrauterine exposures influencing fetal growth. However, we have used 
the presence/absence and direction of association in 3,886 mother-offspring pairs to 
indicate whether the intrauterine environment causes changes in adult offspring SBP (see 
Supplementary Table 18 for full results). 
 
b. Our results demonstrate that the observed negative correlation between birth weight 
and later SBP may be driven by the causal effect of higher maternal SBP on lower offspring 
birth weight (red arrow), in combination with the subsequent transmission of SBP-
associated alleles to offspring (blue arrow), which then increase offspring SBP, rather than 
by long-term developmental compensations to adverse intrauterine conditions. 
 
SEP, socio-economic position; BW, birth weight; SBP, systolic blood pressure. 
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